Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study.
Eline C.H.M. Haijen, Petra P.M. Hurks, Kim P.C. Kuypers
Neurosci Appl October 26, 2022 DOI: 10.1016/j.nsa.2022.101012 via PubMed Central
Summary
AI-generated from the abstractAdults with ADHD who microdosed classic psychedelics on their own initiative reported reduced ADHD symptoms and improved well-being after two and four weeks, compared with their baseline. Performance on a time perception task did not improve. Taking conventional ADHD medication alongside microdosing or having other mental health conditions did not alter the effects on symptoms or well-being after four weeks. The authors call for placebo-controlled experiments to determine whether microdosing offers a genuine benefit beyond the placebo effect.
Study at a glance
| Characteristics | Prospective study Placebo-controlled Peer reviewed |
|---|---|
| Sample size | 233 |
| Population | Adults with ADHD who intended to start microdosing on their own initiative |
| Duration | 4 weeks |
| Citations | 17 |
| Key finding | Microdosing classic psychedelics was associated with decreases in ADHD symptoms and increases in well-being, but not with improved time perception, and effects were unchanged by concurrent medication use or comorbidities. |
Abstract
ADHD in adulthood is often overlooked, which negatively affects the individual's well-being. First-line pharmacological interventions are effective in many ADHD patients, relieving symptoms rapidly. However, there seems to be a proportion of individuals who discontinue, or fail to respond to these treatments. For these individuals, alternative treatment options should be explored. A retrospective survey study reported that using classic psychedelics in low, repeated doses, so called microdosing (MD), was rated as being more effective than conventional treatments for ADHD. The current prospective study aimed to measure the effect of MD on ADHD symptoms, well-being and time perception. Adults with ADHD who had the intention to start MD on their own initiative to self-treat their symptoms were measured before MD and two- and four weeks later. It was expected that ADHD symptoms would decrease, well-being would increase, and performance on a time perception task would improve after MD. It was investigated if conventional medication use alongside MD and comorbidities alongside ADHD influenced the effect of MD. Sample sizes included N=233, N=66, and N=47, respectively. The results showed decreases and increases in ADHD symptoms and well-being, respectively. No improved performance on a time perception task was found. Conventional medication use and having comorbidities did not change the effect of MD on ADHD symptomatology and well-being after four weeks of MD. Placebo-controlled experimental studies are needed to explore further whether there is a beneficial effect of MD for ADHD, beyond the placebo-effect.